JDRF-CIHR partnership supports UBC diabetes research precision medicine teams
JDRF-CIHR partnership supports UBC diabetes research teams with transformative type 1 diabetes (T1D) precision medicine research awards.
The JDRF-CIHR Partnership to Defeat Diabetes is a collaboration between the Government of Canada, through the Canadian Institute of Health Research (CIHR) and JDRF Canada for a total combined investment of $30 million to support transformative type 1 diabetes (T1D) research.
Congratulations to these two University of British Columbia teams for their successful transformative type 1 diabetes grants:
- Precise treatment for pediatric diabetes: Providing the right care, for the right patient, at the right time, over time
Led by BC Children’s Hospital Pediatric Endocrinologist Dr. Shazhan Amed (University of British Columbia), along with her team Dr. Mark Clements (Children’s Mercy Hospital), Dr. Tricia Tang (UBC), and Dr. Wyeth Wasserman (UBC BC Children’s Hospital Research Institute) will receive 3.5 million to expand TrustSphere. The team’s goal is to create a collaborative care experience, improve diabetes self-management, and ultimately improve lives for children and youth with T1D.
- Leveraging biological sex and genetics for beta cell-directed precision medicine in type 1 diabetes
Led by UBC Department of Cellular and Physiological Sciences Associate Professor Dr. Elizabeth Rideout (University of British Columbia), along with her team including Dr. James Johnson (UBC Life Sciences Institute), Dr. Dan Luciani (UBC BC Children’s Hospital Research Institute), Dr. Peter Thompson (University of Manitoba), and Dr. Bruce Verchere (UBC BC Children’s Hospital Research Institute). The team will receive $3.5 million to examine beta cell function between males and females, which will inform T1D prevention and treatment strategies that account for the impact of biological sex.
Read more about JDRF-CIHR partnership announcement and the other two funded precision medicine research projects.